Welcome to our dedicated page for Majestic Ideal SEC filings (Ticker: MJID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Majestic Ideal's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Majestic Ideal's regulatory disclosures and financial reporting.
Ping An Biomedical Co., Ltd. announced a major leadership transition. In October 2025, the Board accepted the immediate resignations of its Chair (Ms. Yuk Yin Judy Li), Chief Executive Officer and Director (Ms. Lina Jiang), Chief Financial Officer (Ms. Xueyuan Chen), and an independent director (Mr. Taylor Carl Coplen). The company stated each resigned for personal reasons and not due to any disagreement with the company or Board on operations, policies, or practices.
New leadership was appointed effective October 14, 2025. Mr. Pijun Liu was named Chairman, Chief Executive Officer, and Executive Director; Ms. Hongli Yang was appointed Chief Financial Officer; and Mr. Xianzhi Liu joined as an independent director. The filing includes brief professional backgrounds for each appointee.
FAQ
What is the current stock price of Majestic Ideal (MJID)?
What is the market cap of Majestic Ideal (MJID)?
